thought call dog
aducanumab file delay perplex
maintain call yield question answer aducanumab
bla biolog licens applic file alzheim diseas aducanumab far
biggest valu driver almost exclus drive bull case
file push earli without clear reason add
uncertainti recogn complex regulatori packag given uniqu
circumst halt futil incomplet dataset post-hoc analys
need activ engag fda said phase data hardli unequivoc
real updat sinc ctad meet dec suggest fda dialogu
could drive delay net-net think delay lower likelihood broad
first cycl approv especi pre-bla meet necessari fda
first character support
look perform deliv upsid ms sma
driven part one-tim event includ less channel inventori de-stock
y/i extra ship day ms sma build due
increas sign price/ share erosioninclud entry/ market
growth new competitor zolgensma risdiplam ozanimod ofatumumab
forecast top- bottom-lin cagr respect vs large-
cap peer respect near-term approv aducanumab
look unlik remain cautiou reiter u/p po
adu embark re-dos studi initi unlik includ file
tysabri trial focal epilepsi discontinu despit still
expect major major studi read-out track still
limit paus studi molecul suppress immun system
updat model continu forecast revenu
reduc non-gaap ep estim page
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
global biotechnolog compani
develop manufactur market therapi
multipl sclerosi oncolog inflammatori
tysabri tecfidera combin
consider share world-wide
rate under-perform given
concern posit compani
commerci portfolio ms franchis
spinraza face meaning commerci
headwind pipelin focus early-
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
million ex per share item
million ex per share item
net incom non-gaap
price object base sum-of-th part npv analysi forecast sale
key product use wacc vari termin growth rate
asset base characterist patent life
assumpt valu entir ms franchis spinraza
collabor revenu biosimilar pipelin net
cash net po
upsid risk po better expect sale tecfidera less eros
avonex plegridi tysabri anticip vumer meaning captur
market share strong durabl spinraza success number early-stag
pipelin program result acceler approv develop
downsid risk greater expect moder ms sale avonex plegridi
tysabri due increas competit rapid eros spinraza market share
sma limit success pipelin mani product fail advanc
approv narrow indic smaller patient popul
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
